Skip to content

Insider · CIK 0001855187

Patricia Menendez-Cambo

director

Files at EXPE (Expedia Group, Inc.). First filing -, latest -.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Oct 1, 2026EXPE
Expedia Group, Inc.
AGrant or award
Stock Unitsderivative
+65$0.00$02,0717 d ago
Jan 1, 2026EXPE
Expedia Group, Inc.
AGrant or award
Stock Unitsderivative
+60$0.00$01,895Jan 5, 2026
Oct 1, 2025EXPE
Expedia Group, Inc.
AGrant or award
Stock Unitsderivative
+79$0.00$01,835Oct 2, 2025
Jul 1, 2025EXPE
Expedia Group, Inc.
AGrant or award
Stock Unitsderivative
+66$0.00$01,756Jul 2, 2025
Jun 1, 2025EXPE
Expedia Group, Inc.
MOption exercise
Common Stock
+871$0.00$06,663Jun 3, 2025
Jun 1, 2025EXPE
Expedia Group, Inc.
MOption exercise
Common Stock
+738$0.00$07,401Jun 3, 2025
Jun 1, 2025EXPE
Expedia Group, Inc.
MOption exercise
Common Stock
+644$0.00$08,045Jun 3, 2025
Jun 1, 2025EXPE
Expedia Group, Inc.
MOption exercise
Restricted Stock Unitsderivative
-644$0.00$00Jun 3, 2025
Jun 1, 2025EXPE
Expedia Group, Inc.
MOption exercise
Restricted Stock Unitsderivative
-871$0.00$0871Jun 3, 2025
Jun 1, 2025EXPE
Expedia Group, Inc.
MOption exercise
Restricted Stock Unitsderivative
-738$0.00$01,477Jun 3, 2025
Jun 1, 2025EXPE
Expedia Group, Inc.
AGrant or award
Restricted Stock Unitsderivative
+1,499$0.00$01,499Jun 3, 2025
Apr 1, 2025EXPE
Expedia Group, Inc.
AGrant or award
Stock Unitsderivative
+100$0.00$01,690Apr 2, 2025
Jan 1, 2025EXPE
Expedia Group, Inc.
AGrant or award
Stock Unitsderivative
+87$0.00$01,590Jan 2, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.